HEM Pharma

At a glance

HEM Pharma filed 59 disclosures in the last 12 months, including 11 insider, 9 5% holder, 3 contract, 1 issuance and 1 m&a. The most recent key filing was on Aug 20: Director's holding fell by 36,000 sh (other change).

Revenue for 2025 was ₩13B, down 13.9% on 2024. It made an operating loss of ₩15.6B. Debt was 894% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9.5B and operating loss of ₩6.7B.

The 2025 annual report lists 101 employees with an average tenure of 3 years and average pay of ₩55.3M, #1431 of 2,191 listed companies by average pay. Its 11 directors and auditors were paid ₩69.7M each on average. It paid no cash dividend for 2025. 지요셉 and related parties held 25.96% at year end.

Of 5 recent 5%+ holder reports, 0 raised and 4 cut a stake; the largest stake reported was 27.98% on Dec 26.

From the 2025 annual report

Staff: 101 (40 men, 61 women), of whom 38 on fixed-term contracts. Total pay for the year: ₩5.6B. Directors and auditors: 11, paid ₩766.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

지요셉 holds 12.26%; with 11 related parties the group holds 25.96% of common shares at year end (from 25.43% at the start of the year).

Individuals paid ₩500M or more

Auditor: 대주회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

3 new supply contracts worth 107% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports